Emalex Biosciences Acquired by Teva | Healthcare M&A Deal

Teva has acquired Emalex Biosciences, a pharmacy business in the United States, for $196 million. Teva acquisitions focus on expanding neuroscience and adding an NDA-ready, first-in-class therapy pipeline through the Emalex Biosciences acquisition. Emalex Biosciences develops healthcare M&A assets aimed at advancing treatment options, supporting Teva’s strategic acquisition strategy in pharmacy and specialty therapeutics. The add-on acquisition is an announced strategic acquisition by Teva, with customary regulatory approvals required to close and an expected completion subject to deal conditions.